Carbapenems have long been the last dependable class for serious Gram-negative infections. Where bacteria carry carbapenemases, that safety net fails, and hospital teams have to plan around a short list of newer agents. This article reports the published data on one of them, aztreonam-avibactam, alongside the supply points hospital pharmacies and procurement teams in India weigh. It does not recommend any treatment.
Why carbapenem-resistant infections are hard to treat
Carbapenem resistance in Enterobacterales commonly comes from enzymes called carbapenemases. Serine carbapenemases such as KPC and OXA-48 can be addressed by some β-lactam/β-lactamase-inhibitor combinations, for example ceftazidime-avibactam (Zavicefta). Metallo-β-lactamases (MBLs) are harder: they hydrolyze nearly all β-lactams except monobactams, and aztreonam alone can still be degraded by other enzymes the same bacteria carry. That is the gap aztreonam-avibactam was developed to address.
How aztreonam-avibactam works
Aztreonam is a monobactam, so it is not broken down by MBLs. Avibactam is a β-lactamase inhibitor that protects aztreonam from serine β-lactamases. Together they combine aztreonam’s stability to MBLs with protection from the other enzymes. Our listing for Emblaveo (aztreonam-avibactam) describes a powder for concentrate for solution for infusion, given intravenously.
What regulators approved
On 7 February 2025 the US FDA approved aztreonam-avibactam, used with metronidazole, for adults aged 18 and over with complicated intra-abdominal infections (cIAI) who have limited or no alternative treatment options. The label lists activity against E. coli, K. pneumoniae, K. oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex and Serratia marcescens. Pneumonia is not an approved indication.
What the REVISIT trial reported
REVISIT was a phase 3 trial of 422 patients randomized 2:1. In the cIAI cohort, 312 patients received aztreonam-avibactam plus metronidazole or meropenem with or without colistin, for 5 to 14 days. The primary end point was clinical cure at test of cure. The trial pre-specified no formal inferential hypotheses, so the figures below are descriptive.
| Outcome | Aztreonam-avibactam | Comparator (meropenem ± colistin) |
|---|---|---|
| cIAI clinical cure, intent-to-treat | 76.4% | 74% |
| cIAI clinical cure, clinically evaluable | 85.1% | 79.5% |
| HAP/VAP clinical cure, intent-to-treat | 45.9% | 41.7% |
| Microbiological response | 75.7% | 73.9% |
| 28-day mortality | 1.9% | 2.9% |
For the cIAI intent-to-treat difference of 2.4%, the reported 95% confidence interval ran from −12.5 to 19.1, which is wide. Readers should treat these as exploratory trial figures and not as proof of superiority.
Safety information in the label
The US label states a contraindication in patients with hypersensitivity to aztreonam or avibactam. Warnings include hypersensitivity reactions, serious skin disorders, transaminase elevations and Clostridioides difficile-associated diarrhea. Adverse reactions in more than 5% of patients included hepatic reactions, anemia, diarrhea, hypokalemia and pyrexia. Always check current prescribing information.
Other agents hospitals consider
Cefiderocol is another newer option for resistant Gram-negative infections. See our post on Fetroja (cefiderocol) in India and the Fetroja product page. Meropenem remains the common carbapenem comparator (Meroplan). Choice among agents depends on local susceptibility data, infection site and the treating team’s judgment, not on a distributor.
Supply and access planning for imported antibiotics
- Verify the pack: confirm strength, manufacturer, marketer, batch and expiry against the carton. Listings can differ between EU and US presentations.
- Stewardship approvals: restricted antibiotics usually pass through the hospital antimicrobial stewardship or infection control committee, so allow time for approval before stock is needed.
- Stock timing: demand is episodic and urgent. Agree lead times with the supplier instead of relying on emergency orders.
- Genuine supply: source from a distributor that can document origin and paperwork. See our guide on verifying genuine imported medicines.
- Access routes: medicines not routinely stocked in India may be available through the Named Patient Program.
A.K. Pharma is a medicine distributor in Delhi supplying hospitals, clinics and doctors.
Frequently asked questions
What are carbapenem-resistant infections?
They are infections caused by bacteria, such as certain Enterobacterales, that no longer respond to carbapenem antibiotics like meropenem. Resistance often comes from enzymes called carbapenemases.
Why are metallo-β-lactamase producers difficult to treat?
Metallo-β-lactamases hydrolyze nearly all β-lactam antibiotics except monobactams such as aztreonam, which leaves very few options. Aztreonam alone can be broken down by other enzymes the same bacteria carry.
What does avibactam add to aztreonam?
Avibactam protects aztreonam from serine β-lactamases, so the combination is active where aztreonam alone would be degraded.
What did the FDA approve on 7 February 2025?
The FDA approved aztreonam-avibactam, used with metronidazole, for adults 18 and over with complicated intra-abdominal infections who have limited or no alternative treatment options.
What did the REVISIT trial report?
In the cIAI intent-to-treat group, clinical cure was 76.4% with aztreonam-avibactam plus metronidazole versus 74% with meropenem with or without colistin. The trial pre-specified no formal inferential hypotheses.
Is pneumonia an approved indication?
No. Hospital-acquired and ventilator-associated pneumonia were studied in REVISIT but are not an approved indication for aztreonam-avibactam.
What safety information appears in the label?
The label lists contraindication with hypersensitivity to aztreonam or avibactam, and warnings for hypersensitivity reactions, serious skin disorders, transaminase elevations and C. difficile-associated diarrhea.
What should a hospital pharmacy verify before stocking an imported antibiotic?
Strength, manufacturer, marketer, batch, expiry and storage against the carton and current prescribing information, plus documentation of origin from the supplier.
Is this article medical advice?
No. A.K. Pharma is a distributor, not a healthcare provider. Treatment decisions rest solely with the treating physician.
Sources
REVISIT figures: Healio report of the IDWeek 2023 presentation. FDA approval and indication: AbbVie press release on the FDA approval. Product details: A.K. Pharma listing.
Disclaimer: A.K. Pharma is a medicine distributor, not a healthcare provider. This article reports published trial and regulatory information and is not medical advice. Treatment decisions rest solely with the treating physician.
